10580. The level of IPTG-induced PT expression was, however, lower than that found for the wild-type B. pertussis Tohama I strain. The TnfusPT minitransposon contains a promoterless PT operon which is only expressed after insertion of the transposon downstream of an appropriately oriented indigenous promoter. After "promoter probing" of B. bronchiseptica with the transposon, clones were screened for PT production by immunoblotting with specific monoclonal antibodies. One clone, designated B. bronchiseptica 10580:: TnfusPTI, expresses significantly higher levels of PT than does B. pertussis Tohama I. The recombinant toxin produced was biologically active in the Chinese hamster ovary cell-clustering assay. High-level expression of PT from a B. bronchiseptica host promoter should provide better yields of the toxin from bacteria not producing other bvg-regulated pathogenesis factors that may play a role in the undesired side effects of current pertussis vaccine preparations.
Increasing concern about side effects of immunization with whole-cell preparations of Bordetella pertussis has, in several countries, led to decreased acceptability of whooping cough vaccines and a consequent increase in the incidence of the disease. It is imperative that an effective, nonreactogenic vaccine of higher acceptability be developed. Potentially protective antigens that are candidates for inclusion in a purified component vaccine include toxins, such as pertussis toxin (PT) and adenylate cyclase, and several cell surface or secreted antigens like filamentous hemagglutinin (FHA) and serotype-specific fimbriae (33, 34) . Purification of antigens directly from B. pertussis is hampered by phase variation controlled by the bvg (Bordetella virulence gene) positive regulatory locus (12, 19, 49) , the presence of reactogenic contaminants, poor bacterial growth rates, and low yields from this nutritionally fastidious microorganism. To circumvent these problems, attempts have been made to obtain expression of recombinant antigens in Escherichia coli by using strong transcriptional and translational signals. The five genes encoding PT have been separately cloned and expressed in E. coli under the control of the lambda PL promoter (6) . The serotype 2 fimbrial subunit has also been expressed from the lambda PL and PR promot-assemble into products that were immunologically identical to the native antigens. Recombinant serotype 2 fimbriae have been produced in Bordetella parapertussis and Bordetella bronchiseptica strains under the control of the native B. pertussis promoter and in B. bronchiseptica under the control of the lac promoter (46) . Pertussis holotoxin has also been produced in recombinant B. parapertussis and B. bronchiseptica strains under the control of the original B. pertussis promoter, although the level of expression obtained was less than that in wild-type B. pertussis and such expression remained subject to modulation and bvgcontrolled phase variation. Recombinant broad-host-range plasmids carrying the PT operon were also extremely unstable, being subject to both plasmid loss and gene deletions (21) .
Pertussis toxoid will be a central component of newgeneration vaccines, and the development of a system for the stable production of high yields of toxin free of potential reactogenic virulence determinants which may play a role in the observed side effects of pertussis vaccination is a major preoccupation of a number of laboratories. In this report, we describe the construction of minitransposons for the stable expression of native pertussis holotoxin in a bvg-negative strain of B. bronchiseptica. This strategy, in combination with methods for the genetic detoxification of PT (18, 23, 30) , should provide a source for the production of E. coli JM109 endAl recA hsdR supE thi gyr lac-pro F' tra-36 proAB lacPZ M15 was used as the recipient strain in cloning steps not involving pUT derivative plasmids (51); E. coli CC118(Apir) was used as the recipient strain for pUT derivatives (14) ; E. coli SM10(Apir) (27) was used to mobilize pUT derivatives (8, 14) to B. bronchiseptica. The plasmids used in this work were pRK600 (9), pDSK519 (17) , and pUC18 (51) . pRMB2 (4, 25) was used as a source of the bvg operon. pTX42 (22) was a kind gift from J. Keith and was used as a source of the PT operon, pUC18NotI (14) , pUT::miniTnS/Km (8) , and pUT::TnPtac, which was constructed by V. De Lorenzo.
E. coli was grown on Z agar (45), X-Gal (5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside) medium (24) , and
Luria broth (24) , and Bordetella spp. were grown on BG agar or in SS broth (43 (24) . Plasmids were isolated by alkaline lysis (24) . Transformation was carried out as described by Hanahan (13) . Agarose gel electrophoresis was performed as previously described (45) . Southern transfer and DNA hybridization with nick-translated DNA as a probe were performed as described by Maniatis et al. (24) . Chromosomal DNA was isolated as described previously (32) . DNA sequencing was carried out by the chain termination method (37) . Taq polymerase (Boehringer) was used as described by Scharf (41) . The polymerase chain reaction (PCR) primers PT-5'XbaI (5'-GGTCTAGAATCAAAACG CAGAGGGGAAGA-3') and PT-3'XbaI (5'-CCAGGTCTA GAACGAATA-3') used for cloning the transcriptional start site (31) and S1 subunit cistron of the PT operon as an XbaI fragment (XbaI sites are underlined) were synthesized by using an Applied Biosystems model 380B DNA synthesizer in accordance with the manufacturer's instructions.
Transfer of plasmids to B. bronchiseptica. E. coli strains containing both pRK600 and pDSK519 derivatives or E. coli SM10(Apir) containing pUT derivatives was grown overnight in nutrient broth with antibiotic selection. A 1.0-ml sample of culture was pelleted by centrifugation at 3,000 x g for 15 min and resuspended in 1.0 ml of 0.9% NaCl. The suspension was used to overlay 1- 50 p.l of the culture onto a nylon membrane (Biodyne A, Pall), and then performing essentially the same procedure used for Western blotting after the transfer step. For immunoelectron microscopy, antibodies were purified from rabbit antisera raised against pertussis toxoid (29) by using a protein A-Sepharose CL-4B column (Pharmacia) as described in the manufacturer's instructions.
Electron microscopy. For fimbrial labeling, thin carbon support film was prepared by indirect sublimation of carbon onto freshly cleaved mica. By using 400-mesh copper grids, the respective strains were then negatively stained with 4% (wt/vol) uranyl acetate (pH 4.5) by the procedure of Valentine et al. (44) . For whole-cell labeling, bacterial strains grown on plates were gently suspended in 250 ,u1 of PBS, absorbed onto freshly prepared collodium-covered nickel grids, and then rinsed with distilled water. After air drying, the grids were treated with a 1:25 dilution of the purified PT-specific IgG antibody (200 ,ug of IgG protein per ml) for 30 min at room temperature. Unbound antibody was removed with a mild spray of PBS from a plastic bottle. The bound antibodies were made visible for electron microscopic examination by incubating the grids on drops of protein A-gold complexes (10-nm gold particle size at an optical density at 520 nm of 0.01) for 10 min at room temperature.
The protein A-gold complexes were prepared by established procedures (42 (19, 49) . It would be advantageous to produce pertussis vaccine components in bvg-negative Bordetella spp. and hence achieve the biological separation of vaccine components from other bvg-regulated virulence factors that may play a role in the observed side effects of whole-cell vaccines. The B. bronchiseptica strains used in this work were studied for the production of FHA and fimbriae to determine the bvg status of these strains. By using electron microscopy and the anti-FHA monoclonal antibody P12H3 in Western blots, it was found that strain 5376 produced both fimbriae (Fig. 1A) and FHA (results not shown). On the other hand, strain ATCC 10580 failed to express either of these bvg-regulated genes (Fig. 1B and results not shown) . However, the latter strain converted to a Fim+ (Fig. 1C) Fha+ (results not shown) phenotype through acquisition of pMW132 (Fig. 1D) , a plasmid constructed by insertion of the B. pertussis bvg operon present in pRMB2 (4, 25) into the broad-host-range vector pDSK519. After transfer of this plasmid to ATCC 10580, transconjugants were found to have a small-colony morphology as previously noted by other workers (25, 28) . B. bronchiseptica bvg-negative derivatives can arise through spontaneous small deletions or frameshift mutations occurring in the bvg locus (28) . However, no obvious deletion of the bvg operon of ATCC 10580 could be detected by Southern hybridization of EcoRI-digested chromosomal DNA by using the cloned bvg determinant as a probe (Fig. 1E ), indicating that a deletion of less than 100 bp (which would be undetectable by Southern analysis) or a frameshift mutation had occurred.
Broad-host-range plasmid-based expression of PT from the lac promoter and native B. pertussis promoter. The PT operon was subcloned into the broad-host-range plasmid pDSK519 to assess the utility of the lac promoter and the native B. pertussis promoter in B. bronchiseptica. The complete PT operon was cloned as an EcoRI-BamHI fragment to produce pMW120, in which the PT operon is oriented counter to that of the lac promoter. Plasmid pMW121 contains the XbaIBamHI fragment containing the S2-, S4-, S5-, and S3-subunit cistron part of the operon inserted into pDSK519, such that these cistrons are read from the lac promoter. Primers PT-5'XbaI and PT-3'XbaI were used in a PCR amplification experiment to isolate a DNA fragment containing the transcriptional start site of the PT operon (31) , and the S1 subunit cistron, flanked by XbaI sites, was cloned into pUC18 to produce pMW123. This XbaI fragment was subsequently ligated to the genes encoding the S2, S4, S5, and S3 subunits contained within pMW121 to construct pMW124, which contains the PT operon under the control of the lac promoter (Fig. 2) . Plasmids pDSK519, pMW120, and pMW124 were transferred to B. bronchiseptica 5376 and analyzed for PT expression. Although the lac promoter directed significantly greater levels of PT than the native B. pertussis bvg-regulated promoter, these constructions did not attain the level of PT production found in B. pertussis Tohama I (Fig. 3) . PT expression from pMW124 was not influenced by the presence or absence of 1 mM IPTG, indicating that this strain did not contain a lac repressor that could regulate the lac promoter (results not shown).
Construction of the minitransposons TnPtacPT and Tnfus-PT and their integration into the chromosome of B. bronchiseptica ATCC 10580. Minitransposons containing the PT operon were constructed to hyperexpress PT in bvg-negative B. bronchiseptica ATCC 10580. The PT operon was cloned from pMW124 into pUC18NotI to provide flanking NotI sites for insertion into the pUT::miniTnS chromosomal integration system. The promoterless PT operon was subcloned from pMW125 as a NotI fragment in the same orientation as the tac promoter of pUT: :TnPtac to form pMW126 (TnPtac-PI) and in the opposite orientation in pUT::miniTn5/Km to produce pMW127 (TnfusPT) (Fig. 4) . After mobilization of pMW126 and pMW127 from E. coli to B. bronchiseptica ATCC 10580, transconjugants were screened for PT production (by colony immunoblotting and Western blotting) and loss of the suicide vector (by kanamycin resistance and ampicillin sensitivity). The levels of PT expression by different TnPtacPT transconjugants (including one transconjugant designated ATCC 10580::TnPtacPTJ) were similar and were less than that by B. pertussis (Fig. 5) ; PT expression was dependent upon the presence of IPTG (results not shown). On the other hand, fewer than 10% of transconjugants containing TnfusPT expressed PT, and the level of PT expression in those that did varied greatly (results not shown), as would be expected from "promoter probing" with a transposon designed to produce transcriptional fusions between native promoters and the promoterless PT operon. One selected TnfusPT transconjugant (ATCC 10580: :TnfusPTI) directed substantially higher levels of PT expression than did B. pertussis (Fig. 5) . To confirm the chromosomal location of both TnPtacPTJ and TnfusPTJ and the loss of the suicide vector, total DNA from ATCC 10580, ATCC 10580::TnPtacPTI, and ATCC 10580::TnfusPTI was digested with EcoRI and subjected to Southern hybridization analysis by using pMW126 as a probe (Fig. 6 ). The loss of the Characterization of PT expression in B. bronchiseptica ATCC 10580::TnfusPTI. The stabilities of plasmid-encoded PT (pMW124) and transposon-encoded PT (TnfusPTJ) expressed in ATCC 10580 were compared after growth in SS-X medium (Table 1) . Clearly, even after 60 generations without antibiotic selection, transposon-encoded PT appeared to be stable. On the other hand, plasmid-encoded PT was very unstable. PT production was 100% linked to kanamycin resistance in strains containing or having previously contained pMW124, indicating that internal deletions of the PT operon had not occurred. Growth rates and levels of PT production in ATCC 10580, ATCC 10580::TnfusPTI, and B. (Cp) alone or in combination with kanamycin (Km).
b A total of 100 Cpr colonies were screened for PT production by colony immunoblotting.
c A total of 100 Cpr Kmr colonies were screened for PT production by colony immunoblotting. pertussis Tohama I were analyzed (Fig. 7A and B) . Although the growth rate of B. bronchiseptica ATCC 10580: :TnfusPTJ was slower than that of the nonmutant parent strain ATCC 10580, the transposon-containing strain still grew significantly faster than B. pertussis (Fig. 7A) . Moreover, high levels of surface-expressed recombinant PT produced from B. bronchiseptica were detected after 18 h of growth, whereas equivalent amounts of PT were only produced by B. pertussis after 36 h of growth (Fig. 7B) . in the periplasm and on the cell surface of ATCC 10580: :TnfusPTJ (Fig. 7C to H) . Unlike the situation with B. pertussis (16) previously described (26) . Compared with pertussis holotoxin prepared from B. pertussis, these preparations contained relatively higher levels of PT subunits S3 and S4 (Fig.  8A) . Witvliet et al. (50) have shown that the S3-S4 dimer contains a carbohydrate binding receptor. Perhaps the preponderance of S3 and S4 reflects efficient binding of the S3-S4 dimer to heparin, a linear glycosaminoglycan (26) . Si and S2 (and presumably S5, which was not detected because of the lack of an anti-S5 antibody) were coeluted with S3 and S4 from the heparin column, suggesting that recombinant holotoxin is formed in the bacterial periplasm. To determine if this was the case, recombinant PT preparations were assayed for biological activity by use of the CHO cellclustering assay. Since our recombinant PT preparations contained proteins other than PT subunits after heparin chromatography (results not shown), monoclonal antibody E19, which specifically binds to the Si subunit of PT and inhibits CHO cell clustering by PT, was used to demonstrate the specificity of any biological activity of the toxin preparation. Tested wild-type and recombinant pertussis holotoxins were adjusted to similar S1 subunit concentrations as assessed by comparative Western blot analysis (results not shown). As shown in Fig. 8B and C, recombinant PT produces the same morphological effect as PT isolated from B. pertussis ( Fig. 8E and F) , at equivalent concentrations, and this activity was specifically inhibited by monoclonal antibody E19 (Fig. 8D and G) .
DISCUSSION
Previous efforts to produce recombinant PT include expression of separate PT subunits in E. coli (6) and Bacillus subtillus (36, 38) and pertussis holotoxin in B. parapertussis and B. bronchiseptica (21) . PT subunits expressed separately in E. coli were nonprotective as assessed in a standard animal model (6). Plasmid-specified PT expression in Bordetella spp. was found to be unstable, gave low product yields, and was subject to phase variation (21) . In this report we describe the stable, high-level expression of PT in bvgnegative B. bronchiseptica. The use of such strains offers several advantages for the production of PT for vaccine purposes, including fast bacterial growth rates, high yields, and the absence of other bvg-controlled virulence determinants in PT preparations.
The PT operon was cloned by using PCR methodology to construct minitransposons (8, 14) . The transposase function is lost with the suicide delivery vehicle, which ensures that further transposition and transposon-mediated gene deletions and rearrangements do not occur (8, 14 (8, 14) , the use of minitransposons containing different antibiotic resistance markers (8, 14) could yield bvg-negative strains containing multiple insertions, thereby creating vaccine production strains capable of yielding multiple antigens. In a study of the stability of plasmid-encoded PT (pMW124) and minitransposon-encoded PT (TnfusPTI), it was found that after 60 generations without antibiotic selection, less than 1% of tested bacteria contained the plasmid (pMW124) or produced PT, whereas 100% of bacteria still contained TnfusPTI and expressed PT. Other workers have also shown that plasmids derived from pLAFR2 or pRSF1010 and encoding the native PT operon are unstable (21) .
PT active in the CHO cell-clustering assay was produced by B. bronchiseptica ATCC 10580::TnfusPTJ. Burns et al. association of the Si subunit with the B oligomer (S2 to S5). The induction of low-level CHO cell clustering by individual components that has been observed was most likely due to cross-contamination with the S1 subunit or the B oligomer, since recombinant Si subunit purified from E. coli fails to exhibit any CHO cell-clustering activity yet restores purified B oligomer to full toxic activity (2) . Periplasmic extracts prepared from B. bronchiseptica ATCC 10580::TnfusPTJ bacteria contained recombinant PT exhibiting CHO cellclustering activity, demonstrating that pertussis holotoxin is formed in the periplasm of the bvg-negative production strain. Periplasmic extracts contain both recombinant pertussis holotoxin and PT dimers (S3-S4), indicating that holotoxin and dimer formation are not dependent on bvgregulated gene products. However, unlike the case with B. pertussis (16) and recombinant bvg-positive B. parapertussis and B. bronchiseptica (21) , holotoxin was not secreted from growing bacteria. To determine whether PT secretion is controlled by a bvg-regulated secretion system, we are currently constructing isogenic bvg-positive and bvg-negative strains of Bordetella spp. which express PT. The identification and cloning of genes involved in PIT secretion and their expression in B. bronchiseptica would further facilitate the purification of recombinant PIT.
Genetically detoxified analogs of PT, expressed in either B. pertussis or B. parapertussis, have been developed by several groups (18, 23, 30) . We expect that the production of detoxified PT in bvg-negative B. bronchiseptica would be accompanied by the same benefits (i.e., increased bacterial growth rates, stable expression, high yields, the absence of other bvg-controlled virulence determinants in PT preparations, and the lack of phase variation) as those described here for recombinant PT. Experiments designed to express genetically detoxified PT in bvg-negative B. bronchiseptica are currently in progress.
